Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157432 | 0.79 | CYP11B2 (0.44) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL2158156 | 0.77 | MKNK1 (0.39) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL7964580 | 0.76 | CYP11B2 (0.43) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL7964582 | 0.76 | CYP11B2 (0.43) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL2158122 | 0.76 | CYP11B2 (0.43) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL7946379 | 0.75 | CYP11B2 (0.42) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL895772 | 0.74 | MKNK1 (0.41) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL7953077 | 0.73 | MKNK1 (0.40) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL2158254 | 0.73 | MKNK1 (0.43) | KCNH2MKNK1MKNK2CSNK1DCSNK1E | |
| SCHEMBL2157354 | 0.73 | MKNK1 (0.39) | KCNH2MKNK1MKNK2CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | MIGNANI SERGE (FR) | 2002-01-17 | — | — | US | disclosed |
| EP-1086100-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064419-A1 | PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006380-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | TNF, IL2, ZC3HAV1 | KCNH2 365/4885MKNK1 4073/4885MKNK2 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.